iiinova — where your digital self keeps evolving

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/04/2026

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial academic.oup.com/jnci/advance... Adding pertuzumab to trastuzumab and chemotherapy🧪 improved invasive DFS across biomarker-defined subgroups

011

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/01/2026

Dear Colleagues Coming February 2026: The 6th Annual OncoAlert Colloquium 🚨 REGISTER👉 oncoalert.m-pages.com/7I0mwF/the-2... As ALWAYS ✅Patients Included #BreastCancer Day Feb 3, 2026 @hoperugo.bsky.social 🇺🇸 @erikahamilton9.bsky.social 🇺🇸 @drsgraff.bsky.social 🇺🇸 @elisaagostinetto.bsky.social 🇧🇪

011

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 22/10/2025

Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa... 50 of our PICKS of TOP Trials out of Berlin 🇩🇪 @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social

021

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 30/09/2025

The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin

264

Elisa Agostinetto @elisaagostinetto.bsky.social · 17/09/2025

I am thrilled to start the #ESMO Leadership Program 2025/26 with such an amazing class of colleagues from all over the world! 🌎 Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀 @myesmo.bsky.social @oncoalert.bsky.social

080

Reposted by Elisa Agostinetto

Nature Reviews Cancer @natrevcancer.nature.com · 05/08/2025

#ResearchHighlight In a study published in #Cell, Phelps et al. find a mechanism connecting exercise, gut microbiota & anti-tumour immunity; exercise induces microbiota to produce formate, which in turn enhances CD8+ T cell functionality. 👇

nature.com

No strain, no formate gains - Nature Reviews Cancer

In a study published in Cell, Phelps et al. find a mechanism connecting exercise, gut microbiota and anti-tumour immunity; exercise induces microbiota to produce formate, which in turn enhances CD8+ T cell functionality.

064

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/07/2025

The OncoAlert WEEKLY RoundUp 🚨 Covering TOP of the week July 11-17 www.youtube.com/watch?v=N9lO... REGISTER👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @realbowtiedoc.bsky.social @drnataliagandur.bsky.social

youtube.com

The OncoAlert 🚨Weekly Round Up July 11-17, 2025 (VIDEO)

YouTube video by OncoAlert 360

042

Reposted by Elisa Agostinetto

COR2ED Medical Education @cor2ed.com · 26/05/2025

📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer cor2ed.com/n-connect/pr... This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only

cor2ed.com

ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium | COR2ED

In this conference update video, Profs. Wolfgang Janni, Sherko Kümmel and Michail Ignatiadis provide key insights from the highly anticipated ESMO Breast

033

Reposted by Elisa Agostinetto

European Cancer Organisation @europeancancer.bsky.social · 05/06/2025

ECO & IPOS bring you a powerful online roundtable exploring how empathy shapes cancer care, and how we can better support the professionals delivering it. Join the discussion on 🗓️ Tuesday, 25 June at 🕓 16:00–17:30 CEST. Register now 🔗 www.europeancancer.org/events/363:y...

043

Elisa Agostinetto @elisaagostinetto.bsky.social · 29/05/2025

Are you a young oncologist attending #ASCO25? Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫 Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/... @oncoalert.bsky.social @ascocancer.bsky.social

061

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/05/2025

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 @elisaagostinetto.bsky.social‬ @erikahamilton9.bsky.social‬ @drsgraff.bsky.social‬ @elisabettabonzano.bsky.social‬

0128

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2025

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB Today we present @E_de_Azambuja 🇧🇪of @JulesBordet who talks to us about the Final Analysis of the APHINITY trial just Presented at #ESMOBreast25 youtu.be/ydcXe_faQH0 A sub analysis was just published out on European Journal of Cancer:

youtu.be

VJ OA Oncology Journal Club: Final Results of the APHINITY Breast Cancer Trial Presented at ESMO ...

Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025.

032

Reposted by Elisa Agostinetto

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social

062

Elisa Agostinetto @elisaagostinetto.bsky.social · 13/05/2025

Right before the start of #ESMOBreast25, our last article is now out in #EJC In this sub-analysis of the APHINITY trial led by @ChiaraDauccia, overweight/obesity was associated with poorer survival outcomes 50-days free access link👇🏻 authors.elsevier.com/a/1l5DL3QE--... @oncoalert.bsky.social

authors.elsevier.com

031

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/05/2025

The OncoAlert🚨Newsletter Now Out Covering May 2-8, 2025 REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... ✅DESTINY-Breast11 Update from Industry ✅PEACE V STORM in #Prostate Cancer⛈️🕊️☢️ ✅OS🧬EGFR-mutant Advanced🫁Non-Small Cell #LungCancer Treated with 1L Osimertinib and more

254

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/05/2025

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study www.thelancet.com/journals/lan... Findings provide robust evidence to guide counselling and management decisions for young BRCA carriers with prior breast cancer

041

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 07/05/2025

NEWS FROM INDUSTRY🚨 Source AstraZeneca DESTINY-Breast11 Update DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen www.astrazeneca.com/media-centre...

164

Elisa Agostinetto @elisaagostinetto.bsky.social · 25/04/2025

I am so grateful that our work has been awarded with a #ConquerCancer #ASCO Merit Award! 💫 Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸 @oncoalert.bsky.social

041

Elisa Agostinetto @elisaagostinetto.bsky.social · 24/04/2025

Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity In this review we address this topic👇🏻 @oncoalert.bsky.social www.sciencedirect.com/science/arti...

021

Elisa Agostinetto @elisaagostinetto.bsky.social · 03/04/2025

Now out our work on a large cohort (n=859‼️) of patients with #breastcancer and leptomeningeal metastases🧠 Happy to share that our work results from an international collaboration of young oncologists committed to advance cancer research👇🏻 @oncoalert.bsky.social doi.org/10.1016/j.br...

doi.org

Redirecting

010

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 20/03/2025

Effect of BMI on #BreastCancer stage and #BreastCancer specific survival link.springer.com/article/10.1... Findings highlight the need for more comprehensive assessments of body composition and metabolic health in BC patients. @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social

0105

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 14/03/2025

Free & On Demand Breast Cancer UPDATE Brought to you by OncoAlert & Partners DIRECT LINK/WATCH HERE👉 buff.ly/myqd20R Join the Breast Cancer Faculty @hoperugo.bsky.social @drsgraff.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social @elisaagostinetto.bsky.social

073

Elisa Agostinetto @elisaagostinetto.bsky.social · 25/02/2025

I am very proud to see published in #JCO the results of our global collaboration🌎 led by @matteolambe showing different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, and the impact of timing of genetic testing on prognosis @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

0102

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 09/02/2025

The #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 buff.ly/4hKRVdM @FernandoOnco 🇧🇷 of Brazil Covering How I Treat #BreastCancer When I dont have the resources Log in to chat with Dr. Moura Patients living in LMICs suffers larger gaps during breast cancer, particularly in public healthcare

033

Elisa Agostinetto @elisaagostinetto.bsky.social · 17/01/2025

🇮🇹The OncoAlert Colloquium by @oncoalert.bsky.social si avvicina! 3-9 Febbraio, 100% virtuale, interattivo e completamente gratuito. Link per registraz ⬇️ 🇧🇪🇫🇷L’OncoAlert Colloquium s’approche! Du 3 au 9 février, 100% virtuel, interactif et complètement gratuit Lien pour s’inscrire⬇️ buff.ly/3CChgre

buff.ly

The 5th Annual OncoAlert Colloquium

The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!

051

Elisa Agostinetto @elisaagostinetto.bsky.social · 11/01/2025

Now out in Cancer Treatment Reviews a nice review on CAR-T cell therapy for #breastcancer, a still experimental approach but with promising expectations for future development and implementation in clinical practice @oncoalert.bsky.social www.sciencedirect.com/science/arti...

sciencedirect.com

CAR-T cell therapy for breast cancer: Current status and future perspective

Within the expanding therapeutic landscape for breast cancer (BC), metastatic breast cancer (MBC) remains virtually incurable and tend to develop resi…

041

Elisa Agostinetto @elisaagostinetto.bsky.social · 10/01/2025

Trastuzumab-pertuzumab-taxane is the SoC 1️⃣line for metastatic HER2+ breast cancer; yet, taxane may induce neurotoxicity. The EMERALD trial now out in @JCO_ASCO investigated the role of eribulin instead of a taxane in this setting ⬇️ @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

ascopubs.org

ASCO Publications

072

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/01/2025

The OncoAlert Video Journal: "Deep Learning Model for Predicting Immunotherapy Response in Advanced #NSCLC Non−Small Cell #LungCancer 🫁" This Week @biagioricciutimd.bsky.social 🇺🇸of @danafarbernews.bsky.social Guides us through his paper out on JAMA oncology www.youtube.com/watch?v=LuD4...

youtube.com

OncoAlert Video Journal: Dr.Ricciuti/Deep Learning Model for Predicting IO ResponseNSCLC Lung Cancer

YouTube video by OncoAlert 360

1176

Reposted by Elisa Agostinetto

Kristina Jankovic @kjankovic.bsky.social · 04/01/2025

In an exploratory analysis of the #PALLAS trial, @elisaagostinetto.bsky.social et al. 💡explored impact of concomitant use palbociclib 💊with PPIs on survival outcomes 📊in #breastcancer . Read more in @ESMO_Open 👇🏻 sciencedirect.com/science/articl… @oncoalert.bsky.social #Oncology

sciencedirect.com

031

Elisa Agostinetto @elisaagostinetto.bsky.social · 04/01/2025

Today the Office of the US Surgeon General advisory released a report on Alcohol and Cancer Risk 🍷 Consuming alcohol ⬆️ the risk of at least 7 types of cancer, including #breastcancer @oncoalert.bsky.social www.hhs.gov/surgeongener...

0124

Elisa Agostinetto @elisaagostinetto.bsky.social · 04/01/2025

At #SABCS24 the updated survival results of the OLYMPIA trial were presented @FrancoisDuhoux and I discussed with @Medi_Mix these clinically relevant data and implications for daily clinical practice ⬇️ @oncoalert.bsky.social medimix.be/onco/sabcs-s...

083

Reposted by Elisa Agostinetto

The OncoAlert Network 🚨 @oncoalert.bsky.social · 03/01/2025

Join OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer #SABCS24 Link to view: buff.ly/4iSMoU6 Dr. @elisaagostinetto.bsky.social interviews Dr. Souza, discussing the safety and impact of this therapy.

051

Elisa Agostinetto @elisaagostinetto.bsky.social · 27/12/2024

Also at Christmas.. the @oncoalert.bsky.social newsletter is out!!!🎄✨ Register at Oncoalert360.com to receive it in your inbox 📥

oncoalert360.com

063